中华胃肠外科杂志
中華胃腸外科雜誌
중화위장외과잡지
CHINESE JOURNAL OF GASTROINTESTINAL SURGERY
2009年
4期
346-349
,共4页
陈超武%黄忠诚%刘云%袁志军%宁国庆%谭立新
陳超武%黃忠誠%劉雲%袁誌軍%寧國慶%譚立新
진초무%황충성%류운%원지군%저국경%담립신
结直肠肿瘤%肿瘤转移%肝%热休克蛋白%化疗
結直腸腫瘤%腫瘤轉移%肝%熱休剋蛋白%化療
결직장종류%종류전이%간%열휴극단백%화료
Colorectal neoplasms%Neoplasm metastasis,liver%Heat-shock proteins
目的 探讨热休克蛋白(HSP)70和HSP90的表达与结直肠癌肝转移化疗疗效的关系.方法 分析52例手术切除了原发病灶而未能切除肝转移病灶并进行奥沙利铂、氟尿嘧啶及四氢叶酸钙化疗方案(FOLFOX4方案)化疗的结直肠癌肝转移患者的临床资料,通过CT检查比较化疗前后肝转移病灶数目及大小的变化:采用亲和免疫组织化学方法测定原发肿瘤组织HSP70和HSP90的表达:分析HSP70和HSP90的表达与化疗疗效间的关系.结果 HSPT0高表达者.部分缓解(PR)率为33.3%,低表达者PR率为64.5%,两者差异有统计学意义(P<0.05);HSP90高表达者,PR率为50%,低表达者PR率为53.1%,两者差异无统计学意义(P>0.05).结论 对于HSP70低表达的结直肠癌肝转移患者,FOLFOX4方案化疗的疗效可能优于HSP70高表达者:HSP90的表达与其疗效无关.
目的 探討熱休剋蛋白(HSP)70和HSP90的錶達與結直腸癌肝轉移化療療效的關繫.方法 分析52例手術切除瞭原髮病竈而未能切除肝轉移病竈併進行奧沙利鉑、氟尿嘧啶及四氫葉痠鈣化療方案(FOLFOX4方案)化療的結直腸癌肝轉移患者的臨床資料,通過CT檢查比較化療前後肝轉移病竈數目及大小的變化:採用親和免疫組織化學方法測定原髮腫瘤組織HSP70和HSP90的錶達:分析HSP70和HSP90的錶達與化療療效間的關繫.結果 HSPT0高錶達者.部分緩解(PR)率為33.3%,低錶達者PR率為64.5%,兩者差異有統計學意義(P<0.05);HSP90高錶達者,PR率為50%,低錶達者PR率為53.1%,兩者差異無統計學意義(P>0.05).結論 對于HSP70低錶達的結直腸癌肝轉移患者,FOLFOX4方案化療的療效可能優于HSP70高錶達者:HSP90的錶達與其療效無關.
목적 탐토열휴극단백(HSP)70화HSP90적표체여결직장암간전이화료료효적관계.방법 분석52례수술절제료원발병조이미능절제간전이병조병진행오사리박、불뇨밀정급사경협산개화료방안(FOLFOX4방안)화료적결직장암간전이환자적림상자료,통과CT검사비교화료전후간전이병조수목급대소적변화:채용친화면역조직화학방법측정원발종류조직HSP70화HSP90적표체:분석HSP70화HSP90적표체여화료료효간적관계.결과 HSPT0고표체자.부분완해(PR)솔위33.3%,저표체자PR솔위64.5%,량자차이유통계학의의(P<0.05);HSP90고표체자,PR솔위50%,저표체자PR솔위53.1%,량자차이무통계학의의(P>0.05).결론 대우HSP70저표체적결직장암간전이환자,FOLFOX4방안화료적료효가능우우HSP70고표체자:HSP90적표체여기료효무관.
Objective To investigate the association between expressions of HSP70, HSP90 and efficacy of chemotherapy in eolorectal cancer patients with unresectable liver metastasis. Methods Data of 52 colorectal cancer cases, whose primary colorectal focuses were resected but hepatic metastatic tumors were unresectable, were reviewed retrospectively. All the patients underwent FOLFOX4 regimen well. Immunohistochemistry assay was applied to determine the expressions of HSP70 and HSP90 in primary focus tissues. The number and size of hepatic metastatic tumors pre- and post-chemotherapy were compared by CT scanning. Results Partial remission (PR) rate was 33.3% in cases with up-regulated expression of HSPT0, while 64.5% in eases with down-regulated expression of HSP70, whose difference was significant. PR rate was 50% in cases with up-regulated expression of HDP90, and 53.1% in the others with down-regulated expression of HSP90, whose difference was not siguificant. Conclusions FOLFOX4 regimen has advantages in cases with lower HSP70 expression over those with higher HSP70 expression. HSP90 expression level is not associated with the efficacy of FOLFOX4 regimen.